NCM
VTGN icon

Nantahala Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Nantahala Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,978,492
Closed -$7.02M – 171
2025
Q3 		$7.02M Hold
1,978,492
– – 0.24% 90
2025
Q2 		$3.96M Hold
1,978,492
– – 0.16% 101
2025
Q1 		$4.95M Sell
1,978,492
-3,488
-0.2% -$9.87K 0.2% 69
2024
Q4 		$5.85M Buy
1,981,980
+464,284
+31% +$1.31M 0.25% 71
2024
Q3 		$4.57M Hold
1,517,696
– – 0.23% 75
2024
Q2 		$5.28M Hold
1,517,696
– – 0.31% 58
2024
Q1 		$8.01M Sell
1,517,696
-299,034
-16% -$1.44M 0.46% 45
2023
Q4 		$9.34M Buy
+1,816,730
New +$6.88M 0.56% 38

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Nantahala Capital Management's VTGN Position: Q4 2025 in Review

Nantahala Capital Management sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 1,978,492 shares — an estimated $7.02M sold.

Nantahala Capital Management first reported a position in VTGN in Q4 2023 and held it in 8 quarters. The position peaked at $9.34M in Q4 2023. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Nantahala Capital Management reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 1,978,492 VistaGen Therapeutics shares in Q4 2025, an estimated $7.02M.
  • Nantahala Capital Management first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 8 quarters.
  • Nantahala Capital Management's VistaGen Therapeutics position peaked at $9.34M in Q4 2023.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.